Serum Institute of India
Tracked across 8 events · 2027 articles · First seen Mar 09, 2018 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Manufacturing partner investing over $100 million; strengthens its vaccine portfolio and global reach.
Jul 16, 2026 · 14 articles
Tech
Impact: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.
May 22, 2026 · 36 articles
Tech
Impact: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.
May 28, 2026 · 6 articles
Accidents
The Democratic Republic of the Congo is experiencing its deadliest Ebola outbreak on record, caused by the rare Bundibugyo ebolavirus. As of August 19, 2026, the outbreak has surpassed 5,000 confirmed cases and over 2,300…
Impact: Manufactured 620,000 doses of the Oxford vaccine candidate, positioning itself for large-scale production if trials succeed.
Aug 01, 2026 · 295 articles
Accidents
The Democratic Republic of the Congo is experiencing its largest and fastest-growing Ebola outbreak on record, caused by the rare Bundibugyo virus for which there are no approved vaccines or treatments. The outbreak, declared on…
Impact: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.
Mar 09, 2018 · 543 articles
Accidents
Impact: The Serum Institute of India is fast-tracking the development and production of a vaccine candidate targeting the Bundibugyo strain of Ebola, in collaboration with the University of Oxford and CEPI, to address the lack of an approved vaccine for this variant.
May 18, 2026 · 535 articles
Accidents
Impact: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.
May 18, 2026 · 505 articles
Regulatory
Impact: Serum Institute of India is among the domestic manufacturers with dengue vaccine candidates in development, indicating potential future competition.
Jul 20, 2026 · 93 articles
99
Serum Institute of India started productionDRC Ebola outbreak spreads...
70
Serum Institute of India manufactured stockpileDRC Ebola outbreak spreads...
69
Serum Institute of India manufactured stockpileDR Congo Ebola outbreak...
+ 4 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Serum Institute of India live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard